The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Recruiting now

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Phase 2 · randomised · 80 people · 1 site in China · Recruiting now

August 8, 2026
AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM

Phase 2 · randomised · 73 people · 1 site in China · Recruiting now

August 8, 2026
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Phase 2 · 38 people · 4 sites in United States · Recruiting now

August 8, 2026
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Phase 2 · randomised · 60 people · 1 site in United States · Recruiting now

August 8, 2026
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 2 · 110 people · 1 site in United States · Recruiting now

August 8, 2026
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

Phase 2 · randomised · 451 people · 85 sites in 19 countries · Recruiting now

August 8, 2026
FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 2 · 619 people · 33 sites in 2 countries · Recruiting now

August 8, 2026
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Phase 2 · 474 people · 12 sites in United States · Recruiting now

August 8, 2026
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

Phase 4 · randomised · 966 people · 1 site in China · Recruiting now

August 8, 2026
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 2 · 554 people · 49 sites in 10 countries · Recruiting now

August 8, 2026